Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.7% – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price traded down 5.7% during mid-day trading on Monday . The company traded as low as $36.41 and last traded at $36.19. 266,106 shares were traded during mid-day trading, a decline of 18% from the average session volume of 324,345 shares. The stock had previously closed at $38.37.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They set an “overweight” rating and a $57.00 price objective on the stock.

Supernus Pharmaceuticals Price Performance

The company’s 50-day simple moving average is $37.14 and its 200-day simple moving average is $34.53. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 34.92 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter last year, the company earned ($0.29) earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Insider Transactions at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. This trade represents a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,913 shares of company stock valued at $5,687,914. 9.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in SUPN. Pacer Advisors Inc. lifted its stake in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares during the last quarter. Millennium Management LLC lifted its stake in Supernus Pharmaceuticals by 395.1% during the second quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock worth $4,316,000 after purchasing an additional 128,743 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Supernus Pharmaceuticals by 145.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,864 shares of the specialty pharmaceutical company’s stock worth $6,699,000 after purchasing an additional 127,420 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Supernus Pharmaceuticals by 14.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after purchasing an additional 91,354 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.